Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.

Abstract:

:Since preexisting immunity and enhanced infection rates in a clinical trial of an HIV vaccine have raised some concerns on adenovirus (Ad) serotype 5-based vaccines, we evaluated the subgroup D adenovirus serotype Ad19a for its suitability as novel viral vector vaccine against mucosal infections. In BALB/c mice, we compared the immunogenicity and efficacy of E1/E3-deleted Ad19a vectors encoding the influenza A virus (IAV)-derived antigens hemagglutinin (HA) and nucleoprotein (NP) to the most commonly used Ad5 vectors. The adenoviral vectors were applied intranasally and induced detectable antigen-specific T cell responses in the lung and in the spleen as well as robust antibody responses. A prior DNA immunization significantly improved the immunogenicity of both vectors and resulted in full protection against a lethal infection with a heterologous H3N2 virus. Nevertheless, the Ad5-based vectors were slightly superior in reducing viral replication in the lung which corresponded to higher NP-specific T cell responses measured in the lungs.

journal_name

Vaccine

journal_title

Vaccine

authors

Lapuente D,Ruzsics Z,Thirion C,Tenbusch M

doi

10.1016/j.vaccine.2018.02.075

subject

Has Abstract

pub_date

2018-05-03 00:00:00

pages

2712-2720

issue

19

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(18)30262-7

journal_volume

36

pub_type

杂志文章

相关文献

VACCINE文献大全